An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome

Cancer Treatment Reviews

Volumn 36, Issue 2, 2010, Pages 164-176

  Mughal, Tariq I ^a   Ejaz, A Ahsan ^b   Foringer, John R ^c   Coiffier, Bertrand ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

Acute kidney injury; Hyperuricemia; Rasburicase; TLS; Tumor lysis syndrome; Uric acid

Indexed keywords

ALLOPURINOL; ASPARAGINASE; AZACITIDINE; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CHLORPROPAMIDE; CISPLATIN; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; DICOUMAROL; FLAVOPIRIDOL; GEMCITABINE; GLUCONATE CALCIUM; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; POLYSTYRENESULFONATE SODIUM; RASBURICASE; STREPTOZOCIN; TEMSIROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; ANTIMETABOLITE; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; ALLERGIC REACTION; ANURIA; BURKITT LYMPHOMA; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DIALYSIS; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; ELECTROCARDIOGRAPHY; ELECTROLYTE BALANCE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEART ARRHYTHMIA; HEMATURIA; HEMOLYSIS; HEPATORENAL SYNDROME; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; METHEMOGLOBINEMIA; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SINGLE DRUG DOSE; TUMOR CELL; TUMOR LYSIS SYNDROME; UREMIA; URIC ACID URINE LEVEL; URINALYSIS; URINE VOLUME; VASCULITIS; VOMITING; DIFFERENTIAL DIAGNOSIS; FLUID THERAPY; METHODOLOGY;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FLUID THERAPY; HUMANS; RENAL DIALYSIS; TUMOR LYSIS SYNDROME;

EID: 77950617707     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.11.001     Document Type: Review

References (86)

1. Bessmertny O., Robitaille L.M., Cairo M.S. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Des 2005, 11:4177-4185.
2. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Brit J Haematol 2004, 127:3-11.
3. Hochberg J., Cairo M.S. Tumor lysis syndrome: current perspective. Haematologica 2008, 93:9-13.
4. Locatelli F., Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005, 147:61-68.
5. Rampello E., Fricia T., Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006, 3:438-447.
6. Coiffier B., Altman A., Pui C.H., Younes A., Cairo M.S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008, 26:2767-2778.
7. Chasty R.C., Liu-Yin J.A. Acute tumour lysis syndrome. Brit J Hosp Med 1993, 49:488-492.
8. Seidemann K., Meyer U., Jansen P., Yakisan E., Rieske K., Fuhrer M., et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL: observations from the BFM-trials. Klin Padiatr 1998, 210:279-284.
9. Hande K.R., Garrow G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993, 94:133-139.
10. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
11. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; October 13 [Epub ahead of print].
12. Annemans L., Moeremans K., Lamotte M., Garcia C.J., van den Berg H., Myint H., et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leukemia Lymphoma 2003, 44:77-83.
13. Kedar A., Grow W., Neiberger R.E. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hemat Oncol 1995, 12:129-134.
14. Montesinos P., Lorenzo I., Martin G., Sanz J., Perez-Sirvent M.L., Martinez D., et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008, 93:67-74.
15. Wossmann W., Schrappe M., Meyer U., Zimmermann M., Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003, 82:160-165.
16. Stapleton F.B., Strother D.R., Roy S., Wyatt R.J., McKay C.P., Murphy S.B. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988, 82:863-869.
17. Baeksgaard L., Sorensen J.B. Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol 2003, 51:187-192.
18. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006, 18:773-780.
19. Mott F.E., Esana A., Chakmakjian C., Herrington J.D. Tumor lysis syndrome in solid tumors. Support Cancer Ther 2005, 2:188-191.
20. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. National Cancer Institute. Published April 30, 1999. [accessed 5.10.08].
21. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. National Cancer Institute. Published August 9, 2006. <> [accessed 5.10.08]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
22. Ten Harkel A.D., Kist-Van Holthe J.E., Van W.M., Van der Vorst M.M. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998, 31:27-28.
23. Conger J.D., Falk S.A. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977, 59:786-793.
24. Band P.R., Silverberg D.S., Henderson J.F., Ulan R.A., Wensel R.H., Banerjee T.K., et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970, 283:354-357.
25. Halperin M.L., Cheema D.S., Kamel K.S. Physiology of acid-base balance: links with kidney stone prevention. Semin Nephrol 2006, 26:441-446.
26. LaRosa C., McMullen L., Bakdash S., Ellis D., Krishnamurti L., Wu H.Y., et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007, 22:132-135.
27. Potter J.L., Silvidi A.A. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987, 33:2314-2316.
28. Veenstra J., Krediet R.T., Somers R., Arisz L. Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma: description of 2 cases and a review of the literature on prevention and management. Neth J Med 1994, 45:211-216.
29. Tosi P., Barosi G., Lazzaro C., Liso V., Marchetti M., Morra E., et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008, 93:1877-1885.
30. Mehta R.L., Pascual M.T., Soroko S., Chertow G.M. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288:2547-2553.
31. Jones D.P., Mahmoud H., Chesney R.W. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995, 9:206-212.
32. Karajala V., Mansour W., Kellum J.A. Diuretics in acute kidney injury. Minerva Anestesiol 2009, 75:251-257.
33. Redfors B., Sward K., Sellgren J., Ricksten S.E. Effects of mannitol alone and mannitol plus furosemide on renal oxygen consumption, blood flow and glomerular filtration after cardiac surgery. Intensive Care Med 2009, 35:115-122.
34. Goldman S.C., Holcenberg J.S., Finklestein J.Z., Hutchinson R., Kreissman S., Johnson F.L., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998-3003.
35. Aloprim® (allopurinol sodium) for injection [package insert]. Boca Raton, FL: Nabi; 2003.
36. Zyloprim® (allopurinol) [package insert]. San Diego, CA: Prometheus Laboratories, Inc.; 2003.
37. Elitek® (rasburicase) [package insert]. Bridgewater, NJ: sanofi-aventis; 2008.
38. DeConti R.C., Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966, 274:481-486.
39. Kann H.E., Wells J.H., Gallelli J.F., Schein P.S., Cooney D.A., Smith E.R., et al. The development and use of an intravenous preparation of allopurinol. Am J Med Sci 1968, 256:53-63.
40. Krakoff I.H., Meyer R.L. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 1965, 193:1-6.
41. Krakoff I.H., Balis M.E. Allopurinol in the prevention of hyperuricaemia secondary to the treatment of neoplastic diseases with alkylating agents, adrenal steroids, and radiation therapy. Ann Rheum Dis 1966, 25:651-654.
42. Smalley R.V., Guaspari A., Haase-Statz S., Anderson S.A., Cederberg D., Hohneker J.A. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000, 18:1758-1763.
43. Yeldandi A.V., Yeldandi V., Kumar S., Murthy C.V., Wang X.D., Alvares K., et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991, 109:281-284.
44. Yeldandi A.V., Yeldandi V., Kumar S., Murthy C.V., Wang X.D., Alvares K., et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991, 109:281-284.
45. Pui C.H., Relling M.V., Lascombes F., Harrison P.L., Struxiano A., Mondesir J.M., et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997, 11:1813-1816.
46. Pui C.H., Mahmoud H.H., Wiley J.M., Woods G.M., Leverger G., Camitta B., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697-704.
47. Bosly A., Sonet A., Pinkerton C.R., McCowage G., Bron D., Sanz M.A., et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003, 98:1048-1054.
48. Coiffier B., Mounier N., Bologna S., Ferme C., Tilly H., Sonet A., et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003, 21:4402-4406.
49. Cortes J, Seiter S, Maziarz RT, et al. Superiority of rasburicase versus allopurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: results of a randomized comparative phase III study [abstract 919]. In: Presented at: 50th ASH Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA. [accessed 05.10.08]. http://ash.confex.com/ash/2008/webprogram/Paper1748.html.
50. Jeha S., Kantarjian H., Irwin D., Shen V., Shenoy S., Blaney S., et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005, 19:34-38.
51. Renyi I., Bardi E., Udvardi E., Kovacs G., Bartyik K., Kajtar P., et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathol Oncol Res 2007, 13:57-62.
52. Shin H.Y., Kang H.J., Park E.S., Choi H.S., Ahn H.S., Kim S.Y., et al. Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2006, 46:439-445.
53. Wang L.Y., Shih L.Y., Chang H., Jou S.T., Lin K.H., Yeh T.C., et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006, 115:35-38.
54. Children's Oncology Group. A pilot study to determine the toxicity of the addition of rituximab to the induction and consolidation phases and the addition of rasburicase to the reduction phase in children with newly diagnosed advanced B-cell leukemia/lymphoma treated with LMB/FAB therapy [Study IDs: CDR0000271941, COG-ANHL01P1; ClinicalTrials.gov Identifier: NCT00057811]. ClinicalTrials.org. Published December 2, 2008. [accessed 07.04.03]. http://clinicaltrials.gov/ct2/show/NCT00057811.
55. Johann Wolfgang Goethe University Hospitals. Randomised phase III trial of effectivity and safety of rasburicase compared with allopurinol for treatment of hyperuricemia in patients with acute lymphoblastic leukemia or high-grade NHL with high risk of tumor lysis syndrome (>15yrs) [Study ID: GMALL08; ClinicalTrials.gov Identifier: NCT00199043]. ClinicalTrials.org. Published December 2, 2008. [accessed 12.09.05]. http://clinicaltrials.gov/ct2/show/NCT00199043.
56. M.D. Anderson Cancer Center. Phase 2 study of rasburicase administered by two different schedules (fixed dosing vs. as needed dosing) in patients at high risk or potential risk for tumor lysis syndrome [Study ID: 2006-0918; ClinicalTrials.gov Identifier: NCT00628628]. ClinicalTrials.org. Published December 2, 2008. [accessed 25.02.08]. http://clinicaltrials.gov/ct2/show/NCT00628628.
57. sanofi-aventis. A randomized, multicenter, open-label, comparison of rasburicase (Fasturtec) versus allopurinol for the prophylaxis and treatment of hyperuricemia in chinese patients with leukaemia or lymphoma [Study ID: RASBU_L_00351; ClinicalTrials.gov Identifier: NCT00607152]. ClinicalTrials.org. Published December 2, 2008. [accessed 22.01.08]. http://clinicaltrials.gov/ct2/show/NCT00607152.
58. St. Jude Children's Research Hospital (sanofi-aventis). A study of rasburicase treatment for chemotherapy of malignancy-induced hyperuricemia in patients with a history of asthma allergies [Study ID: RASALL; ClinicalTrials.gov Identifier: NCT00186940]. ClinicalTrials.org. Published December 2, 2008. > [accessed 12.09.05]. http://clinicaltrials.gov/ct2/show/NCT00186940.
59. European Medicines Agency. Fasturtec European Public Assessment Report, revision 11. Published April 27, 2009. [accessed 17.03.09]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/fasturtec/H-331-PI-en.pdf.
60. Hutcherson D.A., Gammon D.C., Bhatt M.S., Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006, 26:242-247.
61. Liu C.Y., Sims-McCallum R.P., Schiffer C.A. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leukemia Res 2005, 29:463-465.
62. McDonnell A.M., Lenz K.L., Frei-Lahr D.A., Hayslip J., Hall P.D. Single-dose rasburicase 6mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006, 26:806-812.
63. Reeves D.J., Bestul D.J. Evaluation of a single fixed dose of rasburicase 7.5mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008, 28:685-690.
64. Trifilio S., Gordon L., Singhal S., Tallman M., Evens A., Rashid K., et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006, 37:997-1001.
65. Chertow G.M., Levy E.M., Hammermeister K.E., Grover F., Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998, 104:343-348.
66. Coca S.G., Peixoto A.J., Garg A.X., Krumholz H.M., Parikh C.R. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis 2007, 50:712-720.
67. Ponte B., Felipe C., Muriel A., Tenorio M.T., Liano F. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transpl 2008, 23:3859-3866.
68. Mehta R.L., Kellum J.A., Shah S.V., Molitoris B.A., Ronco C., Warnock D.G., et al. Acute kidney injury network. Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
69. Vaidya V.S., Waikar S.S., Ferguson M.A., Collings F.B., Sunderland K., Gioules C., et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transplant Sci 2008, 1:200-208.
70. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006, 17:1503-1520.
71. Shimada M., Johnson R.J., May W.S., Lingegowda V., Sood P., Nakagawa T., et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 2009, 24:2960-2964.
72. Antineoplastic Agents. Drug Facts and Comparisons 4.0 [Web]. St. Louis, MO: Wolters Kluwer Health, Inc.; 2009.
73. Skeel R.T. Handbook of cancer chemotherapy 2007, Lippincott, Baltimore, MD. 7th ed.
74. Hsu C.Y., Ordonez J.D., Chertow G.M., Fan D., McCulloch C.E., Go A.S. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008, 74:101-107.
75. Ishani A., Xue J.L., Himmelfarb J., Eggers P.W., Kimmel P.L., Molitoris B.A., et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009, 20:223-228.
76. Iseki K., Oshiro S., Tozawa M., Iseki C., Ikemiya Y., Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001, 24:691-697.
77. Iseki K., Ikemiya Y., Inoue T., Iseki C., Kinjo K., Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004, 44:642-650.
78. Rosolowsky E.T., Ficociello L.H., Maselli N.J., Niewczas M.A., Binns A.L., Roshan B., et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008, 3:706-713.
79. Tomita M., Mizuno S., Yamanaka H., Hosoda Y., Sakuma K., Matuoka Y., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000, 10:403-409.
80. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients. Nephrol Dial Transplant 2006, 21:1248-1252.
81. Uchino S., Bellomo R., Morimatsu H., Morgera S., Schetz M., Tan I., et al. Continuous renal replacement therapy: a worldwide practice survey: the beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intens Care Med 2007, 33:1563-1570.
82. Cho K.C., Himmelfarb J., Paganini E., Ikizler T.A., Soroko S.H., Mehta R.L., et al. Survival by dialysis modality in critically ill patients with acute kidney injury. J Am Soc Nephrol 2006, 17:3132-3138.
83. Palevsky P.M., Zhang J.H., O'Connor T.Z., Chertow G.M., Crowley S.T., Choudhury D., et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359:7-20.
84. Ratanarat R., Brendolan A., Volker G., Bonello M., Salvatori G., Andrikos E., et al. Phosphate kinetics during different dialysis modalities. Blood Purificat 2005, 23:83-90.
85. Michallet A.S., Tartas S., Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther 2005, 2:159-166.
86. Foringer JR, Norris C, Finkel KW. Potassium disorders. In: Molony DA, Craig JC, editors. Evidence-based nephrology. 1st ed. San Francisco, CA: Wiley-Blackwell; 2008. p. 635-6 [Table 56.3].